# EDGAR Filing Document

**Accession Number:** 0001985062
**File Stem:** 0001213900-25-067048
**Filing Date:** 2025-7
**Character Count:** 29346
**Document Hash:** 224acb801949beab6b29175e6b5c5ac4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-067048.hdr.sgml**: 20250723

**ACCESSION NUMBER**: 0001213900-25-067048

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 7

**FILED AS OF DATE**: 20250723

**DATE AS OF CHANGE**: 20250723

**EFFECTIVENESS DATE**: 20250723

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PSYENCE BIOMEDICAL LTD.
- **CENTRAL INDEX KEY:** 0001985062
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288905
- **FILM NUMBER:** 251143911

**BUSINESS ADDRESS:**
- **STREET 1:** 121 RICHMOND STREET WEST PENTHOUSE
- **STREET 2:** SUITE 1300
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5H 2K1
- **BUSINESS PHONE:** 27744604171

**MAIL ADDRESS:**
- **STREET 1:** 121 RICHMOND STREET WEST PENTHOUSE
- **STREET 2:** SUITE 1300
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5H 2K1

**As filed with the Securities and Exchange Commission on July 23, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Psyence Biomedical Ltd.**

(Exact name ofregistrant as specified in its charter)

---

| | |
|:---|:---|
| **Ontario, Canada** | **Not Applicable** |
| (State or Other Jurisdiction of <br> Incorporation or Organization) | (IRS Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **121 Richmond Street West <br> Penthouse Suite 1300 <br> Toronto, Ontario** | **M5H2Kl** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

---

| |
|:---|
| **Psyence Biomedical 2023 Equity Incentive Plan** |
| (Full Title of the Plan) |

---

**Puglisi** & **Associates<br> 850 Library Ave., Suite 204<br> Newark, Delaware 19711**

(Name and address of agent for service)

**(302) 738-6680**

(Telephone number, including area code, of agent for service)

***With copies to:***

 ****

**Ari Edelman**

**Edelman Legal Advisory PLLC**

**400 Rella Boulevard, Suite 165**

**Suffern, New York 10901**

**(845) 533-3435**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934 (the "Exchange Act").

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (the "Registration Statement") is filed in accordance with General Instruction E to Form S-8 under the Securities Act of 1933 to register an additional 70,174 shares of common stock of Psyence Biomedical Ltd. (the "Registrant") reserved under the Psyence Biomedical Ltd 2023 Equity Incentive Plan (as amended, the "Plan").

This Registration Statement incorporates by reference the Registration Statement on Form S-8 (Commission File No. 333-281112) originally filed on July 31, 2024, covering the initial 3,360 shares reserved under the Plan, to the extent not superseded hereby.

**PART I**

**INFORMATION REQUIRED IN THE SECTION lO(a) PROSPECTUS**

**Item 1. Plan Information.\***

**Item 2. Registration Information and Employee Plan Annual Information.\***

\* The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 (Plan Information and Registration Information and Employee Plan Annual Information) will be sent or given to recipients of the grants under the Plan as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Securities and Exchange Commission (the "Commission") and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. The Registrant will provide a written statement to participants advising them of the availability without charge, upon written or oral request, of the documents incorporated by reference in Item 3 of Part II hereof and including the statement in the preceding sentence. The written statement to all participants will indicate the availability without charge, upon written or oral request, of other documents required to be delivered pursuant to Rule 428(b) of the Securities Act, and will include the address and telephone number to which the request is to be directed.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The Registrant is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Commission maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the Commission, including the Registrant. The address for the Commission's website is "http://www.sec.gov." The following documents filed by the Registrant with the Commission are incorporated herein by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l. Our Annual Report on [Form 20-F](https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ea0246623-20f_psyence.htm) which was filed with the Commission
on June 25, 2025 (the "Annual Report") for the fiscal year ended March 31, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The description of our Common Stock filed as [Exhibit 2.4](https://www.sec.gov/Archives/edgar/data/1985062/000141057824001112/pbm-20240331xex2d3.htm) to
the Annual Report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The Current Reports on Form 6-K filed on the following dates: [April 1, 2025](https://www.sec.gov/Archives/edgar/data/1985062/000121390025027251/ea0236551-6k_psyence.htm) , [April 11, 2025](https://www.sec.gov/Archives/edgar/data/1985062/000121390025031060/ea0237635-6k_psyence.htm) (other than exhibit 99.3), [April 23, 2025](https://www.sec.gov/Archives/edgar/data/1985062/000121390025034643/ea0239303-6k_psyence.htm) (other than exhibits 99.2 and 99.3) [June 11, 2025](https://www.sec.gov/Archives/edgar/data/1985062/000121390025053433/ea0245269-6k_psyence.htm) (other than
exhibit 99.2), [June 25, 2025](https://www.sec.gov/Archives/edgar/data/1985062/000121390025057779/ea0246906-6k_psyence.htm) (other than exhibits 99.2 and 99.3); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. All other reports filed pursuant to Section 13(a) or 15(d)
of the Exchange Act since the end of the fiscal year covered by the Annual Report referred to in (a) above.

Except to the extent such information is deemed furnished and not filed pursuant to securities laws and regulations, all documents that we file with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, in each case, subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement (that indicates that all securities offered under this Registration Statement have been sold or that deregisters all securities then remaining unsold) shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents.

Any statement contained herein or in a document all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

The following exhibits are filed herewith:

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description of Exhibit** |
| 4.1 | [Certificate of Incorporation of Psyence Biomedical Ltd. (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).](https://www.sec.gov/Archives/edgar/data/1985062/000110465923117179/tm2320950-15_f4a.htm#tANNB1) |
| 4.2 | [Amended and Restated Bylaws of Psyence Biomedical Ltd. (incorporated by reference to Exhibit 3.3 to the Company's Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).](https://www.sec.gov/Archives/edgar/data/1985062/000110465923117179/tm2320950-15_f4a.htm#tANNXC) |
| 5.1\* | [Opinion of WeirFoulds LLP.](ea025001801ex5-1_psyence.htm) |
| 23.1\* | [Consent of MNP LLP.](ea025001801ex23-1_psyence.htm) |
| 23.2\* | [Consent of WeirFoulds LLP (included in Exhibit 5.1).](ea025001801ex5-1_psyence.htm) |
| 24.1 | [Powers of Attorney (included on the signature page of this Registration Statement)](#poa_001) |
| 99.1 | [Psyence Biomedical Ltd. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 6-K filed with the SEC on July 25, 2025).](https://www.sec.gov/Archives/edgar/data/1985062/000121390025057779/ea024690601ex10-1_psyence.htm) |
| 107\* | [Filing Fee Table](ea025001801ex-fee_psyence.htm) |

---

\* Filed herewith

**Item 9. Undertakings.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this
Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) to include any prospectus required by Section 10(a)(3) of
the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to reflect in the prospectus any facts or events arising
after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or
in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change
in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration
statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) to include any material information with respect to the plan
of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration
Statement; to include any material information with respect to the plan of distribution not previously disclosed in the Registration
Statement or any material change to that information in the Registration Statement

*provided, however,* that paragraphs (a)(l)(i) and (a)(l)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under
the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrant hereby undertakes that, for the
purposes of determining liability under the Securities Act of, each filing of the Registrant's annual report pursuant to Section
13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant
to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be in the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(c) Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions,
or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Toronto, Ontario, Canada on the 23<sup>rd</sup> day of July, 2025.

---

| | |
|:---|:---|
| **Psyence Biomedical Ltd.** | **Psyence Biomedical Ltd.** |
| By: | /s/ Neil Maresky |
|  | Neil Maresky |
|  | Chief Executive Officer |

---

**Power of Attorney**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Neil Maresky and Jody Aufrichtig, each acting alone, as his true and lawful attorneys-in-fact and agents, each with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Neil Maresky | Chief Executive Officer and Director | July 23, 2025 |
| Neil Maresky | (Principal Executive Officer) |  |
| /s/ Warwick Corden-Lloyd | Chief Financial Officer | July 23, 2025 |
| Warwick Corden-Lloyd | (Principal Financial and Accounting Officer) |  |
| /s/ Jody Aufrichtig | Chairman of the Board and Strategic Business Development Officer | July 23, 2025 |
| Jody Aufrichtig |  |  |
| /s/ Marc Balkin | Director | July 23, 2025 |
| Marc Balkin |  |  |
| /s/ Christopher (Chris) Bull | Director | July 23, 2025 |
| Christopher (Chris) Bull |  |  |
| /s/ Seth Feuerstein | Director | July 23, 2025 |
| Seth Feuerstein |  |  |

---

**AUTHORIZED U.S. REPRESENTATIVE**

Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Psyence Biomedical Ltd. has signed this registration statement in the city of Newark, Delaware on the 23rd day of July, 2025.

---

| | |
|:---|:---|
| Puglisi & Associates | Puglisi & Associates |
| By: | *Isl* Donald J. Puglisi |
| Name: | Donald J. Puglisi |
| Title: | Authorized Representative |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| Barristers & Solicitors  | ![](ex5-1_001.jpg) |

---

July 23, 2025

Psyence Biomedical Ltd.

121 Richmond Street West

Penthouse Suite 1300

Toronto, Ontario, M5H 2K1

Dear Mesdames/Messrs:

Re: Registration Statement on Form S-8

We have acted as Canadian corporate counsel to Psyence Biomedical Ltd. (the "**Corporation**"), a corporation incorporated under the laws of Ontario, Canada, in connection with the filing of a registration statement on Form S-8 (the "**Registration Statement**"), by the Corporation with the United States Securities and Exchange Commission (the "**Commission**") under the U.S. Securities Act of 1933, as amended (the "**Securities Act**").

The purpose of the Registration Statement is to register the offer and sale of up to 70,174 common shares in the capital of the Corporation (the "**Common Shares**") which may be issued under the Psyence Biomedical Ltd. 2023 Equity Incentive Plan (as amended from time to time, the "**Plan**").

**Examination of Documents**

In giving the opinions expressed below we have examined:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) a Certificate of Status issued under the *Business Corporations Act* (Ontario) dated July 23, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) a copy of the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the certificate of incorporation, articles and by-laws of the Corporation (the "**Articles** ");
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) certain resolutions of the Corporation's directors and shareholders.

---

| | |
|:---|:---|
| 4100 - 66 Wellington Street West, PO Box 35, TD Bank Tower, Toronto, Ontario, Canada. M5K 1B7 | **T: 416-365-1110 F: 416-365-1876** |
| 4100 - 66 Wellington Street West, PO Box 35, TD Bank Tower, Toronto, Ontario, Canada. M5K 1B7 | www.weirfoulds.com |

---

---

| | |
|:---|:---|
| Barristers & Solicitors  | ![](ex5-1_001.jpg) |

---

**Assumptions and Reliances**

As to certain matters of fact, we have relied on a certificate of an officer of the Corporation of even date (the "**Officer's Certificate**").

In preparation for the delivery of this opinion, we have examined the above-mentioned documents and we have examined all such other documents and made such other investigations as we consider relevant and necessary in order to give this opinion. In particular, we have not reviewed, and express no opinion on, any document that is referred to or incorporated by reference into the documents reviewed by us. As to various questions of fact material to this opinion which we have not independently established, we have examined and relied upon, without independent verification, certificates of public officials and officers of the Corporation including, without limitation, the Officer's Certificate.

For purposes of this opinion letter, we have also assumed:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) the legal capacity of all individuals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) the genuineness of all signatures on, and the authenticity and completeness of all documents submitted
to us as originals and the conformity to authentic or original documents of all documents submitted to us as certified, conformed, telecopied,
photostatic, electronically transmitted copies (including commercial reproductions);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) the identity and capacity of any person acting or purporting to act as a corporate or public official;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the accuracy and completeness of all information provided to us by public officials or offices of public
record;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) the accuracy and completeness of all representations and statements of fact contained in all documents,
instruments and certificates (including the Officer's Certificate);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) the accuracy and completeness of the minute books and all other corporate records of the Corporation reviewed
by us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) the facts stated in the Certificate of Status continue to be true as of the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) all securities referred to herein have been offered, issued and sold in compliance with applicable United
States federal and state securities laws, and in the manner stated in the Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) that the facts stated in the Certificate of Status and the Officer's Certificate shall continue
to be true and correct as at the date of completion of the share issuances contemplated hereby.

---

| | |
|:---|:---|
| Barristers & Solicitors  | ![](ex5-1_001.jpg) |

---

We have not undertaken any independent investigation to verify the accuracy of any of the foregoing assumptions.

When our opinion refers to Common Shares to be issued or having been issued as being "fully paid and non-assessable", such opinion indicates that the holder of such Common Shares cannot be required to contribute any further amounts to the Corporation by virtue of his, her or its status as holder of such Common Shares, either in order to complete payment for the Common Shares, to satisfy claims of creditors or otherwise. We rely on the Corporation's confirmation that it has received, or will receive prior to issuance, full consideration for the Common Shares and no opinion is expressed as to the adequacy of any consideration received for such Common Shares.

We are qualified to practice law only in the Province of Ontario. Our opinion below is limited to the existing laws of the Province of Ontario and the federal laws of Canada applicable therein as of the date of this opinion and should not be relied upon, nor are they given, in respect of the laws of any other jurisdiction. In particular, we express no opinion as to United States federal or state securities laws or any other laws, rule or regulation, federal or state, applicable to the Corporation. We disclaim any obligation or duty to update this opinion to reflect any changes in such laws or other circumstances after the date hereof.

The opinions given below are given as of the date of this letter and are not prospective.

**Opinion**

Based upon and subject to the foregoing, we are of the opinion that, provided that all necessary corporate action has been taken by the Corporation to authorize the issuance of the Share Options (as defined in the Plan), Share Appreciation Rights (as defined in the Plan), Restricted Shares (as defined in the Plan), Restricted Share Units (as defined in the Plan), or Other Share-Based Awards (as defined in the Plan) (collectively, the "**Awards**") which may be issued under the Plan, we are of the opinion that upon the redemption, settlement or exercise of the Awards, as applicable, in accordance with their terms, the Plan and any applicable Award Agreement (as defined in the Plan), the Common Shares underlying the Awards will be validly issued, fully paid and non-assessable shares in the capital of the Corporation.

This opinion letter is rendered as of the date hereof, and is opining upon and is limited to the laws of the Province of Ontario and the federal laws of Canada applicable therein, as such laws presently exist as of the date hereof. We express no opinion with respect to the effect or applicability of the laws of any other jurisdiction. We assume no obligation to revise or supplement this opinion letter should applicable laws be changed after the date hereof by legislative action, judicial decision or otherwise, or if we become aware of any facts that might change the opinions expressed herein after the date hereof. The opinions expressed in this letter are limited to the matters set forth herein and no other opinions should be inferred beyond the matters expressly stated.

We consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the caption "Legal Matters" in the prospectus constituting part of the Registration Statement. In giving this consent, we do not thereby imply or admit that we are an "expert" within the meaning of Section 11 of the Securities Act or the rules and regulations promulgated thereunder or that we come within the categories of persons whose consent is required by Section 7 of the Securities Act.

Yours truly,

/s/ *WeirFoulds LLP*

## Exhibit 23.1

**Exhibit 23.1**

![](ex23-1_002.jpg)

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the Registration Statement on Form S-8, of our auditor's report dated June 25, 2025 relating to the consolidated financial statements of Psyence Biomedical Ltd. and its subsidiaries (the "Company") as at March 31, 2025 and 2024 and for each of the years in the three- year period ended March 31, 2025, as included in the Annual Report on Form 20-F of the Company for the year ended March 31, 2025, as filed with the United States Securities and Exchange Commission.

---

| |
|:---|
| /s/ MNP LLP |
| MNP LLP |
| Chartered Professional Accountants |
| Licensed Public Accountants |
| July 23, 2025 |

---

Toronto, Canada

![](ex23-1_001.jpg)

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Psyence Biomedical Ltd**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered(1) | Proposed Maximum Offering Price Per Share |  | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
| Equity | Common stock, no par value, that may be issued under the Psyence Biomedical Ltd. 2023 Equity Incentive Plan | 457(h) | 70174 | $5.28 | (2) | $370518.72 | 0.00015310 | $56.73 |
| Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  |  | $370518.72 |  | $56.73 |
| Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |  |
| Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  |  | $56.73 |

---

(1) Pursuant to Rule
 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover
 any additional shares of common stock, no par value per share, of the Registrant (the "Common Stock") that may become
 issuable under the Psyence Biomedical Ltd. 2023 Equity Incentive Plan as a result of any stock dividend, stock split, recapitalization
 or other similar transaction which results in an increase in the number of shares of the Registrant's outstanding Common Stock.

(2) Estimated solely
 for the purpose of calculating the registration fee pursuant to Rules 457(h) and 457(c) under the Securities Act, based upon the
 average of the high and low prices of the Common Stock, as reported on the Nasdaq Stock Market on July 18, 2025, which date is within
 five business days prior to the filing of this registration statement.